Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-501 T cells in pediatric hematological disorders
NCT03301168Phase 2Active, not recruiting
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Apr 2014
- Primary completion
- May 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of rivogenlecleucel in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), myelodysplastic syndrome (MDS), primary immunodeficiency disorder (PID), sponsored by Bellicum Pharmaceuticals, Inc.. Started Apr 2014; status: active, not recruiting.
02
Drugs
rivogenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)primary immunodeficiency disorder (PID)
Beyond the preview
Go deeper on NCT03301168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301168.